Both main subtypes of lung cancer, small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC), are sensitive to BET inhibition in several preclinical models. SCLC cell lines are widely sensitive to BETi treatment, and there is growing evidence that BET inhibitors may work to improve the frequency and duration of responses in NSCLC patients. In particular, BET inhibitors synergize with a class of chemotherapeutics called EGFR inhibitors and may also target mechanisms of resistance to these drugs.
Lung cancer is the most common cancer in the world and remains the leading cause of death from cancer in both men and women. Despite the fact that chemotherapies, immunotherapies and several targeted agents are approved for lung cancer, metastatic forms of the disease still generally carry a poor prognosis.
Lung cancer is an active area of research for us, as we explore potential strategies and collaborations to initiate clinical trials in this space.
